OBJECTIVE: We sought to establish the clinical relevance of micrometastatic disease detected by reverse transcription polymerase chain reaction (RT-PCR) in axillary lymph nodes (ALN) of breast cancer patients. BACKGROUND: The presence of ALN metastases remains one of the most valuable prognostic indicators in women with breast cancer. However, the clinical relevance of molecular detection of micrometastatic breast cancer in sentinel lymph nodes (SLN) and nonsentinel ALN has not been established. METHODS: Four hundred eighty-nine patients with T1-T3 primary breast cancers were analyzed in a prospective, multi-institutional cohort study. ALN were analyzed by standard histopathology (H&E staining) and by multimarker, real-time RT-PCR analysis (mam, mamB, muc1, CEA, PSE, CK19, and PIP) designed to detect breast cancer micrometastases. RESULTS: A positive marker signal was observed in 126 (87%) of 145 subjects with pathology-positive ALN, and in 112 (33%) of 344 subjects with pathology-negative ALN. In subjects with pathology-negative ALN, a positive marker signal was significantly associated with traditional indicators of prognosis, such as histologic grade (P = 0.0255) and St. Gallen risk category (P = 0.022). Mammaglobin was the most informative marker in the panel. CONCLUSION: This is the first report to show that overexpression of breast cancer-associated genes in breast cancer subjects with pathology-negative ALN correlates with traditional indicators of disease prognosis. These interim results provide strong evidence that molecular markers could serve as valid surrogates for the detection of occult micrometastases in ALN. Correlation of real-time RT-PCR analyses with disease-free survival in this patient cohort will help to define the clinical relevance of micrometastatic disease in this patient population.
OBJECTIVE: We sought to establish the clinical relevance of micrometastatic disease detected by reverse transcription polymerase chain reaction (RT-PCR) in axillary lymph nodes (ALN) of breast cancerpatients. BACKGROUND: The presence of ALNmetastases remains one of the most valuable prognostic indicators in women with breast cancer. However, the clinical relevance of molecular detection of micrometastatic breast cancer in sentinel lymph nodes (SLN) and nonsentinel ALN has not been established. METHODS: Four hundred eighty-nine patients with T1-T3 primary breast cancers were analyzed in a prospective, multi-institutional cohort study. ALN were analyzed by standard histopathology (H&E staining) and by multimarker, real-time RT-PCR analysis (mam, mamB, muc1, CEA, PSE, CK19, and PIP) designed to detect breast cancer micrometastases. RESULTS: A positive marker signal was observed in 126 (87%) of 145 subjects with pathology-positive ALN, and in 112 (33%) of 344 subjects with pathology-negative ALN. In subjects with pathology-negative ALN, a positive marker signal was significantly associated with traditional indicators of prognosis, such as histologic grade (P = 0.0255) and St. Gallen risk category (P = 0.022). Mammaglobin was the most informative marker in the panel. CONCLUSION: This is the first report to show that overexpression of breast cancer-associated genes in breast cancer subjects with pathology-negative ALN correlates with traditional indicators of disease prognosis. These interim results provide strong evidence that molecular markers could serve as valid surrogates for the detection of occult micrometastases in ALN. Correlation of real-time RT-PCR analyses with disease-free survival in this patient cohort will help to define the clinical relevance of micrometastatic disease in this patient population.
Authors: M Mitas; K Mikhitarian; C Walters; P L Baron; B M Elliott; T E Brothers; J G Robison; J S Metcalf; Y Y Palesch; Z Zhang; W E Gillanders; D J Cole Journal: Int J Cancer Date: 2001-07-15 Impact factor: 7.396
Authors: A Marchetti; F Buttitta; G Bertacca; K Zavaglia; G Bevilacqua; D Angelucci; P Viacava; A Naccarato; A Bonadio; F Barassi; L Felicioni; S Salvatore; F Mucilli Journal: J Pathol Date: 2001-09 Impact factor: 7.996
Authors: M Ooka; I Sakita; Y Fujiwara; Y Tamaki; H Yamamoto; T Aihara; M Miyazaki; M Kadota; N Masuda; Y Sugita; K Iwao; M Monden Journal: Oncol Rep Date: 2000 May-Jun Impact factor: 3.906
Authors: Barbara K Zehentner; Davin C Dillon; Yuqiu Jiang; Jiangchun Xu; Angela Bennington; David A Molesh; XinQun Zhang; Steven G Reed; David Persing; Raymond L Houghton Journal: Clin Chem Date: 2002-08 Impact factor: 8.327
Authors: M Giesing; F Austrup; B Böckmann; G Driesel; C Eder; I Kusiak; B Suchy; P Uciechowski; H J Grill Journal: Int J Biol Markers Date: 2000 Jan-Mar Impact factor: 3.248
Authors: M Mitas; K Mikhitarian; L Hoover; M A Lockett; L Kelley; A Hill; W E Gillanders; D J Cole Journal: Br J Cancer Date: 2002-03-18 Impact factor: 7.640
Authors: Goran Marjanovic; Markus Schricker; Axel Walch; Axel zur Hausen; Ulrich T Hopt; Andreas Imdahl; Frank Makowiec Journal: J Gastrointest Surg Date: 2010-10-26 Impact factor: 3.452
Authors: Steven J Hughes; Liqiang Xi; Siva Raja; William Gooding; David J Cole; William E Gillanders; Keidi Mikhitarian; Kenneth McCarty; Susan Silver; Jesus Ching; William McMillan; James D Luketich; Tony E Godfrey Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: Christian Schem; Nicolai Maass; Dirk O Bauerschlag; Martin H Carstensen; Thomas Löning; Christian Roder; Olivera Batic; Walter Jonat; Katharina Tiemann Journal: Virchows Arch Date: 2008-12-20 Impact factor: 4.064
Authors: Thorsten Heilmann; Micaela Mathiak; Jakob Hofmann; Christoph Mundhenke; Marion van Mackelenbergh; Ibrahim Alkatout; Antonia Wenners; Christel Eckmann-Scholz; Christian Schem Journal: J Cancer Res Clin Oncol Date: 2013-08-02 Impact factor: 4.553
Authors: V Luyckx; J F Durant; A Camboni; S Gilliaux; C A Amorim; A Van Langendonckt; L M Irenge; J L Gala; J Donnez; M M Dolmans Journal: J Assist Reprod Genet Date: 2013-08-29 Impact factor: 3.412
Authors: Steven J Hughes; Liqiang Xi; William E Gooding; David J Cole; Michael Mitas; John Metcalf; Rohit Bhargava; David Dabbs; Jesus Ching; Lynn Kozma; William McMillan; Tony E Godfrey Journal: J Mol Diagn Date: 2009-10-01 Impact factor: 5.568
Authors: Allyson L Valente; Jennifer L Kane; Darrell L Ellsworth; Craig D Shriver; Rachel E Ellsworth Journal: Clin Exp Metastasis Date: 2014-04-01 Impact factor: 5.150
Authors: Mike Visser; Mehdi Jiwa; Anja Horstman; Antoinette A T P Brink; Rene P Pol; Paul van Diest; Peter J F Snijders; Chris J L M Meijer Journal: Int J Cancer Date: 2008-06-01 Impact factor: 7.396